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ABSTRACT 
 
The objective was to develop an economic prioritisation model to assist those involved in (i) the 
selection and prioritisation of health technology assessment topics and (ii) commissioning of 
HTA projects. The model used decision analytic techniques to estimate the expected costs and 
benefits of the health care interventions which were the focus of the HTA question(s) considered 
by the NHS Health Technology Assessment Programme in England. Initial estimation of the 
value for money of HTA was conducted for a number of topics considered in 1997 and 1998.  
The main conclusion was that it is feasible to conduct ex ante assessments of the value for money 
of HTA for specific topics.  However, a considerable amount of work is required to ensure that 
the methods used are valid, reliable, consistent and an efficient use of valuable research time. 
 
 






Given the large number of health technologies that could potentially be evaluated, no country 
has the resources available to undertake all the assessments it would ideally require.  Some 
economies of effort can be realised through the closer collaboration of national health 
technology agencies, for example through the International Association of Health Technology 
Agencies (INAHTA).  However, there is still a need to set priorities among the assessments that 
could be carried out (16,18). 
 
Priorities could be set according to a range of criteria.  An important criterion relates to the 
value, in improved information for decision making, from undertaking a given assessment.  
Some authors have referred to this as ‘payback’ (1).   A number of authors have discussed the  
issue of payback from health technology assessments (HTAs) or approaches to prioritising the 
HTA effort.  In a seminal paper, Eddy (9) outlined a model for determining priorities.  Detsky 
(5) and Drummond et al (7) undertook ex post assessments of particular research studies.  For 
example, Drummond et al estimated the costs and benefits of conducting the Diabetic 
Retinopathy Study (DRS), a large randomised controlled trial of laser photocoagulation 
treatment for diabetic retinopathy.  They considered two states of the world, one with the study 
and one without, and estimated the likely impact of the trial results on the costs and effects of 
treatment. 
 
Buxton and Hannay (1) defined payback in a broader sense, to encompass not only the impact 
of research on health and health care, but also knowledge more generally.  They also suggested 
that research could meet a range of political and administrative needs, and illustrated their 
approach by conducting a number of ex post assessments of a range of research projects 
undertaken in the UK. 
 
A number of authors have recognised the need for ex ante analysis of the value of research and 
the additional challenges this raises.  Attempts by Buxton and Hannay to assess the payback 
from four proposed projects were not very successful.  In addition, preliminary papers from the 
PATHS project (13) outlined a number of difficulties.  However, if HTA agencies are to 
consider value for money or payback in making decisions about priorities for assessments, ex 
ante analyses are required and more exploration of the problems needed (16).  This paper 
addresses these issues in the context of  the support given by the National Coordinating Centre 
for Health Technology Assessment (NCCHTA) for decisions about priorities made by the 
Standing Group for Health Technology Assessment (SGHT), as part of the NHS Research and 
Development Programme in the United Kingdom. 
 
THE NCCHTA AND PRIORITISATION 
 
The National Coordinating Centre for Health Technology Assessment (NCCHTA) was 
established in 1996 to manage and develop the NHS Health Technology Assessment 
Programme. The principal tasks of the NCCHTA are: (i) identification of important (to the 
NHS) under-evaluated health technologies; (ii) supporting the SGHT and its advisory panels in Prioritising Investments in Health Technology Assessment 
 
2 
the clarification and prioritisation of these, through the provision of relevant information; (iii) 
commissioning research; (iv) monitoring and assessing commissioned research; (v) 
communicating openly about the processes and products of the HTA programme. 
 
Each year approximately 1000 potential topics are identified by the NCCHTA, excluding topics 
where there is finished or ongoing research elsewhere.  These are sub-divided into 6 broad 
areas, for discussion by 6 expert panels.  The panels meet bi-annually to prioritise topics in: 
acute sector care; primary and community care; diagnostic and imaging; screening; 
pharmaceuticals and methodology. For the first meeting, the panels are given brief information 
about the technology area, the reason for evaluation, the source of demand for evaluation and 
the patient group.  At this stage the information given to the panels can be very non specific.  
The panels select approximately 100 topics, for which vignettes/expert papers are prepared.   
 
The vignettes summarise available clinical, epidemiological and cost information about the 
topic and broad research questions to be addressed.  At the second round of panel meetings the 
100 topics are discussed in detail.  The technologies, target groups and initial research questions 
are refined and approximately two thirds of the topics are selected for consideration by the 
SGHT.  The SGHT finally selects over 40 topics to be commissioned each year.  
 
The decision making criteria at each of these stages include consideration of economic factors 
and potential value for money in terms of the importance of the question (economic burden of 
disease), the degree of current uncertainty, trajectory of diffusion of the technology, and the 
cost of research.  However, paucity of data make it difficult to quantify all of these variables 
and relate them in an explicit economic framework to assess the potential value for money of 
research.  Thus, there are potential benefits from the development of an economic model to 




A pilot study was conducted to assess the feasibility of providing broad cost and outcome 
information for the first round of the prioritisation process. Three criteria were set to judge the 
quality and potential value of the data.  First, there is complete incidence, cost and outcome data 
on each of the topics considered by a panel.  Secondly, the data could be collected and estimated 
in a consistent fashion.  Thirdly, the topic is sufficiently defined to identify relevant patient 
groups and interventions.   Although a wide range of data was collected, the criteria specified 
above were not met.  Subsequent development work was conducted to develop a model for the 
ex ante analysis of the value for money of commissioning assessments in specific topic areas.  To 
date, this has been constrained to the provision of information to the second stage of the 
prioritisation process. 
 
The approach and economic prioritisation model (EPM) to support the NCCHTA and SGHT at 
the second stage were based on previous methodological expositions (9) and empirical work to 
evaluate the costs and benefits of a clinical trial ex-post (7). This section outlines the key 





The overall purpose of the model was to provide additional information to the SGHT and its 
advisory panels.  Specific uses of the information were to assist those involved in (i) the selection 
and prioritisation of health technology assessment (HTA) topics and (ii) commissioning of HTA 
projects.  The objectives for the development of an economic prioritisation model were to: (i) 
collect, structure and analyse comparative information to assess the relative value-for-money of 
potential HTA questions/topics, in terms of the costs and benefits of HTA to society; (ii) provide 
relevant and useable information to those involved in the decision making process, to improve 
the allocation of resources between potential HTA areas; (iii) identify critical factors that 
determined the value for money of specific assessments,  that should be considered in the process 
of commissioning, disseminating and implementing  HTA evidence.  
 
Perspective  
The EPM was constrained to consideration of HTA funded by the NHS R&D programme.  It 
was assumed that the principal objective of HTA is to provide information and evidence to 
influence health care practice and improve the efficiency of health care provision. The 
perspective of the model included consideration of the costs and benefits to: (i) the research 
funding body; (ii) the providers of health and social care services; and (iii) the patients who are 
likely to receive the health care interventions targeted.   
 
The broader costs and benefits of HTA to society (such as value of knowledge per se, the 
development of research skills, political and administrative benefits, or the costs and benefits to 
other research funding agencies) were excluded.  The main logic for exclusion of these items was 
that, first, they are difficult to assess differentially between competing health technology 
assessments.  For example, benefits to the research infrastructure from HTA’s would accrue 
irrespective of the particular technology evaluated.  In addition, inclusion of political benefits 
among the criteria for investment leads to the question of whether these should also be 
considered in economic evaluation of specific health technologies.  Traditionally, these 
evaluations focus on the benefits in improved health, not the broader political gains (8, 10). 
 
Time frame  
The period covered by the model was the estimated time from commissioning of the research 
(year 1) and initial dissemination of the research findings, to substitution of the health care 
intervention of interest by other new technologies.  A maximum timeframe of 20 years for the 
lifetime of the health care intervention in question was also imposed, on the grounds that the 




The model used decision analytic techniques to estimate the expected costs and benefits of the 
health care interventions which were the focus of the HTA question(s).  It compared the health 
technology of  interest with relevant comparators from standard or usual care.  The expected 
costs were estimated for one year incidence or prevalence cohorts of treated patients.  These data 
were then combined with available information about the: 
 
•  likely rates of utilisation of the new technologies;  
•  probability that the new intervention will be proven effective or ineffective by the HTA;  
•  maximum lifetime for the new technology;  
•  probability of additional new technologies and rates of utilisation;  
•  transition costs of adopting the new intervention;  
•  cost of the HTA.   
 
The model was used to determine the level of uncertainty about clinical and economic evidence, 
and the critical factors which would affect  the potential value for money of the HTA, for each 
topic.   
 
Value of HTA and the EPM 
The final value of HTA was limited to the potential impact of the results on the efficiency of 
health care provision (9). Furthermore, HTA was only deemed to be of value if it was 
instrumental in bringing about changes in health care policy and practice which improved the 
efficiency of health care provision.  Figure 1 illustrates the processes through which HTA can 
change the efficiency of health care provision.  Figure 2 illustrates the range of factors which 
may modify the impact of HTA on the provision of health care. The flow diagram in Figure 3 
illustrates the conceptual structure of the EPM 
 
Process of HTA impact on health care provision 
Figure 1 starts at the point where there is a set of HTA questions or hypotheses to be addressed. 
These can be evaluated by exploratory HTA or confirmatory HTA.  Exploratory HTA is defined 
as primary HTA to tackle questions or hypotheses that have not previously been subjected to 
rigorous or systematic evaluation.  Confirmatory HTA is defined as primary HTA or synthesis of 
available evidence, which adds to the existing body of rigorous or systematic evaluations for 
specific questions.  These questions may have been the subject of previous evaluation.   
Confirmatory HTA may be required if the results of earlier evaluations were thought to be 
uncertain due to perceived flaws in study design, such as inadequate sample size or use of 
inappropriate endpoints, or there are two or more studies where the results are contradictory (4).  
 
The intermediate outputs of either exploratory or confirmatory HTA at this stage are the 
generation of new HTA questions or hypotheses and additions to the existing body of evidence. 
This intermediate set of outputs are highly uncertain and remote from the final outcome of 
efficiency of health care provision.  In addition,  the impact of these factors is likely to be low 
and not amenable to reliable quantification or valuation.  For these reasons the generation of   5
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additional questions or hypotheses were not included as a variable in the economic prioritisation 
model. 
 
Adoption of HTA information 
 
A prerequisite for HTA results to be translated into action to improve efficiency, is that the 
results are disseminated and recognised as relevant and useable evidence by health care policy 
makers and health care professionals.  However, this is not sufficient to ensure that the results 
will be translated into appropriate action.  A number of factors were assumed to affect the 
adoption of HTA results and the provision of health care (Figure 2).  
 
First, it was assumed in the EPM  that the nature of the existing body of evidence and the HTA 
results will affect the process of adoption.  Changes in the practice of health care policy makers 
and professionals are positively, if weakly, related to the quantity and quality of available 
evidence (22, 17, 11, 3, 21, 15).  If the HTA is exploratory rather than confirmatory and existing 
evidence is low or contradictory,  the impact of a specific HTA on practice may also be low.  
Even if the design of the exploratory HTA is sufficient to address the evaluation question with a 
high degree of certainty, there may still be uncertainty about the quality/validity of the evidence. 
 In this case health care decision makers may prefer to wait for additional confirmatory HTA 
before implementing the results.  In contrast, HTA to confirm the existing body of evidence may 
have a relatively higher impact on practice and the efficiency of health care provision.  Results 
which are positive and conclusive are more likely to have an impact on the provision of health 
care than results which are negative or equivocal. 
 
Secondly, it was assumed that the methods of dissemination and implementation will affect the 
extent to which HTA results are known and accepted by health care policy makers and 
professionals.  If health care professionals are to practice evidence based medicine they must 
access and interpret a wide range of HTA based information.  It is also well documented that 
health care professionals (for a variety of reasons) do not review all relevant published evidence 
relating to their practice.  For HTA results to be accepted and have an impact on practice, they 
need to be interpreted and presented in a systematic and accessible manner.  It was assumed that 
HTA which incorporates a coherent and broad ranging dissemination or implementation plan is 
more likely to change practice than HTA which does not.   
 
Thirdly, it was assumed that the adoption of HTA results is affected by factors outside the HTA 
process.  These include, the transitional costs of implementing the results of HTA, in terms of 
investment in new skills or facilities or dis-investment in existing skills and facilities, the advent 
of new interventions and HTA information, the national and local political and organisational 
context, and the belief systems of  health care professionals.   
   7
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Analysis of data 
 
The principal analysis of data was estimation of the expected net costs and benefits of HTA, and 
the level of uncertainty surrounding these estimates.  The model calculated point estimates of the 
expected value for money of a specified piece of HTA. To address uncertainty in the data, a 
minimum and maximum range of estimates of expected value for money were also derived.  
These were based on a number of sensitivity analyses to vary each of the parameters from across 
a range of plausible values.  In addition, threshold analyses were conducted to find the minimum 
(maximum) value at which a variable would need to be set  for the net expected costs and 
benefits of the HTA to be zero, or equivalent to the expected costs and benefits of not 




Initial estimation of the value for money of HTA was conducted for the topics considered by the 
pharmaceutical panel in the second stage of prioritisation in 1997 and 1998.  Table 1 summarises 
the results of the analyses.  The HTA topics are deliberately anonomysed but included a diverse 
range of topics such as therapies for people with mental health problems or ophthalmologic 
diseases.  In the preliminary analysis the data estimates were derived in a short time scale.  
Because of the time constraints, default values or assumptions were used for several of the 
variables used in the model.  These are specified below.   
 
1. The likely rates of utilisation of new technologies were assumed to vary according to the true 
effectiveness of the technologies and the evidence of effectiveness.  It was assumed that the 
level of existing evidence about new technologies will be relatively low or uncertain, leading 
to low rates of utilisation (5% of health care provision for effective technologies and 3% for 
ineffective technologies).  The addition of evidence about effectiveness from new HTA will 
increase the annual rate of utilisation of effective technologies (to 16% per annum) and 
decrease the annual rate of utilisation of ineffective technologies (to 2% per annum) (22, 20, 
14, 12).  The current rate of utilisation of the technology in question was based on information 
from the vignettes, or was assumed to be 5% for effective technologies and 3% for ineffective 
technologies if no data was available. 
2. It was assumed that a proportion of the technologies in question were ineffective.  The chance 
of the technology being effective was assumed to be equal to the rate of new pharmaceutical 
compounds which are successful in phase III clinical trials.  This has been estimated at 67% 
(6). 
3. A maximum lifetime for the new technology was given at 20 years.  During this time the 
technology will be gradually replaced by additional new technologies which will enter health 
care practice and be utilised at the rates given in 1 above. 
4. The transition costs of adopting the HTA results and implementing the new intervention were 
assumed to be zero  unless it was clear that utilisation of the health care intervention would 
require significant (dis)investment in staff, equipment or facilities.   10
Table 1    Expected costs and benefits of HTA: results of payback analyses, pharmaceutical panel, 1997-8 
 
Topic no.  Net expected cost (range)   Net expected benefit of HTA  ICER      Critical determinants of costs/benefits of HTA   
    of HTA £’s million    (improved symptom control)     Cost/benefit  of  Effectiveness  Utilisation  of   
             interventions  of  interventions  interventions 
98-A   +307    (-695,  +1678)   0.6  m  people  with  ISC   494-3020   YES   NO   YES 
98-B   +434    (-88,  +956)   58000  people  with  ISC   2917-16457   YES   YES   NO 
98-C   -315    (-823,  +844)   0     NA    YES   NO   YES 
98-D   +2    (-45,  +50)   0  years  with  ISC   0-746    YES   YES   YES 
98-E    +104   (-118, +339)    2518  cases averted   41000-224133   YES   YES   YES 
98-F   -9    (-409,  +652)   7030  people  with  ISC   0-92745    YES   NO   YES 
98-G    +1122   (+357, +1887)    13432  people with  ISC   26600-140500   YES   NO   YES 
98-H   +136  (-775,  +600)   1819  people  with  ISC   74876-0.3  m   YES   YES   YES 
98-I    +27309  (+10769, +43849)  290484 people with  ISC   37072-150954   YES   YES   NO 
98-J   -59    (-28,  -117)   0     NA    YES   YES   YES 
98-K   +364  (-549,  +15079)   4378  cases  averted   83082-3.4m   YES   NO   YES 
98-L   -860  (-239,  -1238)   0     0    NO   NO   NO 
98-M   +181  (-647,  +1005)   5781  cases  averted   27568-173804   YES   YES   YES 
97-A   -1005  (-1947,  +223)   0     NA    YES   YES   YES 
97-B   +42  (+11,  +50)   1160  life  years  gained   9353-53323   YES   YES   YES 
97-C   +55  (-41,  +84)   448  deaths  averted   0-187500   YES   YES   YES 
97-D   +182  (+2,  +337)   13019  deaths  averted   1313-25892   YES   YES   YES 
97-E   -167  (-167,  +118)   0     NA    NO   YES   NO 
97-F   +333  (+318,  358)   3414  deaths  averted   48990-104730   NO   YES   YES 
97-G   +9  (+8,  +10)   81  deaths  averted   94174-117949   YES   YES   NO 
97-H   -0.2  (-2,  +3.8)   0  cases  averted   0-4445    YES   YES   YES 
97-I   +68  (-51,  +70   1252  life  years  gained   0-55910    NO   YES   YES 
97-J   +1924  (-75,  +1924)   3380  life  years  gained   0-569183   NO   YES   YES 
97-K   +200  (+19,  +259)   8740  life  years  gained   0-29558    NO   NO   NO 
97-L   +15  (-203,  +15)   0     NA    NO   YES   YES    




Overall, it was possible to conduct analyses for 80% of the topics considered by the 
pharmaceutical panel in 1997 and 60% in 1998.  It was not possible to conduct analyses for some 
of the topics due to uncertainty about the topic, the interventions or the patient groups to be 
targeted.  For all of the topics analysed there were sufficient data to generate base case or best 
guess estimates of costs, and to generate a range of costs for sensitivity analysis.  In all the 
analyses the outcome data available were not sufficient to generate one consistent measure of 
patient benefit  (such as the quality-adjusted life year) for all the topics.  This meant that the 
outcomes or benefits reported ranged from measures such as case averted to deaths averted or 
life years gained for the 1997 panel topics, and people with improved symptom control to cases 
averted in the 1998 panel topics.  In addition, there was insufficient information about possible 
ranges in levels of effectiveness on which to base a sensitivity analysis.  The approach taken was 
to use threshold analysis to determine critical levels of effectiveness at which the net benefits of 
the analysis would be zero.  
 
The results from both years’ analyses indicate that, using information routinely available in the 
literature and from the vignettes, it was not possible to estimate the absolute value of HTA with 
any certainty for this stage of the prioritisation process.   Of the topics analysed in 1997, the 
results for 58% were considered uncertain  (i.e. switched from net saving to net cost or vice-
versa) compared with the results for 73% in 1998.  Overall, the results were uncertain for 65% of 
the HTA questions or topics analysed.  
 
As might be predicted, the relative costs of the interventions or technologies compared to 
existing costs of care and likely levels of utilisation were critical factors in the majority of the 
analyses in two respects.  First the level  of  costs extend into the model for the new technology 
and standard or existing care determined whether the analysis switched from net saving to net 
cost in the majority of cases (69%, 1998 and 58%, 1997).  Secondly, a threshold level for one or 
more cost variables was found in 68% of topics (93%, 1998 and 50%, 1997)   
 
The probability that the technology would be found to be effective with the HTA was a critical 
factor in determining the expected costs and/or benefits for 47% (1998) to 92% of topics (1997) 
topics.  Threshold analysis also indicated that the impact of the HTA on the rates of utilisation of 




The preliminary results suggest that it is feasible to conduct ex ante assessments of the potential 
value for money of HTA for some topic areas.  However, the work to date raises a number of 
issues for further consideration.  An underlying set of questions relate to whether continued 
development of the approach, the model and data inputs is a worthwhile activity, compared to the 
methods of prioritisation currently used by the NHS R&D programme or alternative approaches. 
These questions require consideration of a number of factors directly relating to the approach 
taken and development of the model and the relative efficiency of alternative approaches and 
models.   
 Prioritising Investments in Health Technology Assessment 
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Validation of the model and analyses  
 
The first issue is whether the approach and subsequent economic prioritisation model presented 
here are valid in terms of the methodological framework and attributes.  There are several 
components to be addressed.  First, is it legitimate to restrict the scope of the model to the impact 
of HTA on the provision and outcomes of health care, given the likely cost of undertaking the 
research?  As mentioned above, this excludes the broader economic benefits of HTA to other 
sectors of society (13).  Some of these broader consequences may already be taken into account 
in the decision making process.  It is not clear whether quantification and inclusion of these 
factors in the analysis would have a significant impact on the overall results, such that the 
prioritisation or choice of topics to be commissioned would change.  
 
Model specification  
 
The model currently uses a deterministic framework for the analyses with the results determined 
by specified inputs and relationships, rather than a Bayesian or stochastic approach to determine 
the value of information (2, 16).  This means that the complex process of HTA, dissemination 
and utilisation can be analysed in a relatively simple model.   The advantages are that 
deterministic models require relatively fewer data than stochastic models, and require fewer 
resources to run each analysis.  The disadvantages are that for problems where there are complex 
relationships and distributions of data it is difficult to assess the robustness of the results.  In 
particular a deterministic formulation restricts analysis of the extent to which the results are 
uncertain due to a real lack of evidence rather than inaccuracy in the model inputs or 
relationships.  However, the work to date has indicated that in the UK setting, there is a lack of 
data with which to populate a deterministic model.  This problem would be intensified if a 
stochastic model were to be implemented.  In particular, use of an incorrect distribution incurs a 
risk that the results of a stochastic analysis may be even less reliable than a deterministic one.  
The extent of the risk of inaccuracy of the results of the analyses and the subsequent impact on 
the  efficiency of the prioritisation process is unclear.   
 
Decision rules  
 
The data in Table 1 indicate that the results of the majority of analyses were uncertain.  In 
addition, for most cases, the input values for the effectiveness and utilisation rates and the costs 
and benefits of interventions were critical factors.  Changes within a plausible range for these 
variables can switch the results from net saving to net cost (or vice versa).  Even if the input data 
were accurate and a consistent outcome measure could be generated, it is not clear how these 
results should be interpreted and whether they add value to the prioritisation process.  In 
particular, decision rules need to be developed to determine which topics should be prioritised 
for further consideration.  The results for the majority of topics indicate a range from net saving 
to net cost, with a correspondingly large spread of expected cost/outcome estimates.  This makes 




One approach would be to categorise the results on the basis of uncertainty, for example, clearly 
worthwhile funding, uncertain, obviously not worthwhile.   The worthwhile category might 
include those projects where there are always net savings with positive benefits, or cost/QALY 
ratios which are all within a predefined range.  The uncertain category would include those 
topics where the results are sensitive to changes in input parameters or for which thresholds can 
be determined for the critical factors.  The obviously not worthwhile range would include those 
topics where there were always net costs with zero or negative benefits, or where the cost/QALY 
ratios were all outside the predefined range.  Within the uncertain category, projects could then 
be ranked by level of uncertainty.  For example, those projects where no threshold values for 
some of the variables, such as utilisation rates, were defined could be given a lower priority than 
those where thresholds could be defined.  This would require the assumption that HTA should be 
targeted at topics where there is a greater level of uncertainty about current evidence and/or the 
impact of the HTA on health care provision.   
 
Data availability and quality  
 
Epidemiological and economic data were not available for the formal quantification of some 
topics, using routine information sources in the UK.  Furthermore the data were uncertain for one 
or more parameter for each topic. The time constraints imposed by the current prioritisation 
process employed by the NCCHTA mean that the value of HTA cannot be formally quantified 
for all the topics. The need for rapid estimation of the value for money of HTA for a number of 
topics, and the available research resources imposed constraints on the quantity and quality of 
data collected.  Information about the likely impact of new technologies had to be constrained to 
symptom control or improvement, cases cured or prevented, or life years lost/deaths averted for 
some diseases.  The problems in estimating a consistent outcome measure and plausible ranges 
of values have a number of major implications for the analyses.  First, it was not possible to 
compare incremental cost-effectiveness ratios across topics, in isolation from detailed 
information about the disease group and impact of therapy.  Secondly, the sensitivity analysis of 
incremental ratios was driven mainly by changes in cost rather than variations in both costs and 
benefits.  These difficulties were compounded by the use of default values for parameters such as 
annual utilisation rates and probabilities of actual and proven (in)effectiveness.  The information 
for the default values were derived from a limited number of published sources dealing with the 
utilisation and success rates associated with pharmaceutical interventions.   
 
A literature review is currently underway to collect additional information with which to refine 
these estimates and, if possible, generate default values which are at least specific to the general 
themes of the individual panels, if not disease or broad therapeutic groups.  However, this still 
leads to the question of whether the use of default values is plausible and valid for some or all of 
the topics considered.  The analyses to date indicate that the results were sensitive to these 
values.  Inaccurate specification of the default values could bias both the point estimates and the 
analysis of uncertainty.  Refinement of the values for specific topics may reduce the uncertainty 
in the inputs to the model and the interpretation of the results.  However, it is clear that 
uncertainty in the values of all the variables in the model is an inherent factor which determines 
the need for HTA and thus methods of prioritising the HTA agenda. Prioritising Investments in Health Technology Assessment 
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In conclusion, it is clear that it is feasible to conduct ex ante assessments of the value for money 
of HTA for specific topics.  However, a considerable amount of work is required to ensure that 
the methods used are valid, reliable, consistent and are an efficient use of valuable research time. 
 In particular, the relative value of alternative analytic techniques such as option pricing (19), 
data envelopment analysis and stochastic simulations to determine the efficient allocation of 
research resources needs to explored.  In addition, the value of providing decision makers with 
quantitative estimates of the ‘payback’ of health technology assessments needs to be compared 
















1.   APPENDIX 1:  DETAILS OF THE PRIORITISATION MODEL 
 
Expected costs and outcomes of treated disease 
 
The model is built in blocks, starting with estimation of the expected costs and outcomes of the 
new intervention and one or more forms of existing treatment.  The model uses either lifetime 
costs of treatment for one year incidence cohorts (acute diseases of less than 1 year duration), or 





The adoption of HTA results and the utilisation of specific health care  interventions could incur 
(dis)investment costs not directly included in the expected costs of treatment. If incurred, these 
need to be added to the expected costs of the technology assessed.  In addition, transition costs 
may affect the rate of adoption and utilisation of interventions. This is included in the model 
indirectly, by weighting standard utilisation rates for health care interventions or through the 
estimation of rates specific to the interventions studied. 
 
Lifetime of new and future interventions 
 
The model estimates the expected value of HTA over the lifetime of the health care intervention 
in question.  This is either a maximum of 20 years or based on estimates specific to the 
intervention. The maximum of 20 years reflects the effects of discounting the costs and outcomes 
over the life of the intervention. Year 1 of the lifetime for the technologies assessed starts when 
the results of the HTA project are reported. 
 
Utilisation rates of interventions 
 
To calculate the expected costs and outcomes of treatment for each year, the costs and outcomes 
of each intervention considered are multiplied by the estimated net rate of utilisation for that 
year. The model can use either standard estimates of utilisation rates or specific estimates of 
utilisation.  Utilisation rates are estimated for the intervention to be compared to existing 
treatment with and without HTA.  Each of these categories are subdivided into the rates which 
would apply if the intervention was effective or not effective. The utilisation rate for each year is 
estimated from the annual rate of utilisation, the probability of the intervention being proven 
(in)effective by HTA, or being (in)effective for the case where HTA is not undertaken, the 
probability that the dissemination and implementation plan for the HTA results is effective and 
the probability of substitution by future interventions not yet evaluated. 
 
Equations A-E illustrate the calculation of net utilisation rates for the case where the proposed 
HTA will be undertake, and equations F-H where the proposed HTA is not undertaken.  It is 
assumed that the HTA design will be adequate to deliver results which are unequivocal.  For the Prioritising Investments in Health Technology Assessment 
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purposes of this model, effectiveness of new technology or treatment is defined as equivalence 
to, or superiority over, standard or existing care: 
 
Case with HTA 
 
A.  The annual utilisation rate of an effective new technology, when HTA indicates it is effective 
   = Ae + (ARe*PEe*IR) - (UFRnet*0.5), 0<A<1; 
B.  The annual utilisation rate of an effective new technology, when HTA indicates it is 
ineffective  
  = Ae + (ARi*PIe*IR) - (UFRnet*0.5), 0<B<1; 
C.  The annual utilisation rate of an ineffective new technology, when HTA indicates it is 
ineffective  
  = Ai+(ARi*PIi*IR), 0<C<1; 
D.  The annual utilisation rate of an ineffective new technology, when HTA indicates it is 
effective  
  = Ai+(ARe*PIe*IR), 0<D<1; 
E.  The annual utilisation rate of standard or existing technology, with HTA  
  = (1- A - B - C - D -(Z*0.5)), 0<E<1; 
 
Case without HTA 
F.  The annual utilisation rate of an effective new technology, with no HTA  
  = (Ae*Pe)-(Z*0.5), 0<F<1; 
G.  The annual utilisation rate of an ineffective new technology with no HTA  
  = (Ai*Pi), 0<G<1; 
H.  The utilisation rate of standard or existing technology, with no HTA  
  = (1- F - G - (Z*0.5)),  0<H<1; 
 
Where: 
Ae  = the annual probability of utilisation of an effective technology, given existing evidence; 
Ai  = the annual probability of utilisation of an ineffective technology, given existing 
evidence; 
ARe  = the maximum incremental probability of utilisation of an effective technology, new 
evidence; 
ARi  = the maximum incremental probability of utilisation of an ineffective technology, new 
 evidence; 
PEe  = the probability the new HTA indicates an effective new technology is effective; 
PEi  = the probability the new HTA indicates an ineffective new technology is effective; 
PIi  = the probability the new HTA indicates an ineffective new technology is ineffective; 
PIe  = the probability the new HTA indicates an effective new technology is ineffective; 
Pe  = the probability the new technology is effective; 
Pi  = the probability the new technology is ineffective; 
IR  = the probability that dissemination and implementation of new HTA results changes 
practice. 




Costs of HTA 
For the purposes of this model it is assumed that there is no HTA ongoing which could address 
the questions of interest.  The net expected costs (NEC) and benefits (NEB) of conducting the 
HTA are calculated as: 
 
NEC =   [CR + (Dt*((ECnt*A) + (ECnt*B) + (ECMAXnt*C) + (ECMAXnt*D) + (ECst*E))] -
  [(Dt*((ECnt*F ) + (ECMAXnt*G) + (ECst*H))],  
NEB  =    [(Dt*((EBnt*A) + (EBnt*B) + (EBMINnt*C) + (EBMINnt*D) + (EBst*E))] - 
[(Dt*((EBnt*F) +   (EBMINnt*G) + (EBst*H))] 
where, 
CR     = cost of HTA; Dt = discount rate, time t; 
ECnt     = Expected treatment cost of an effective new intervention at time t; 
ECMAXnt  = Expected maximum cost of an ineffective new technology at time t; 
ECst    = Expected cost of standard or existing treatment at time t; 
EBnt     = Expected benefit of an effective new intervention at time t; 
EBMINnt  = Expected benefit of an ineffective new technology at time t; 
EBst    = Expected benefit of standard or existing treatment at time t; 
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